StudyID,Drug_Name,Prot_No,NCT_No,EUCT_No,Other_No,Inv_Prod,Study_Phase,Start_Date,Termin_Date,Complet_Date,Data_Cutoff_Date,Name_PI,Sponsor,GCP_Compliance,Study_First_Posted_Date,Route_Admin,Treat_Duration,Add_On_Treat,Arm_Description,Adherence_Treat,MRCT,No_Center,No_Center_NA,No_Center_AP,No_Center_WEU,No_Center_EEU,No_Center_AF,Enroll_Duration_Plan,FU_Duration_Plan,Central_Lab,Run_in,DMC
NCT01295827,Pembrolizumab,P07990,NCT01295827,2011-002371-42,MK-3475-001; P07990; KEYNOTE-001,Pembrolizumab,Phase 1,"March 4, 2011",,"December 11, 2018",,,Merck Sharp & Dohme LLC,,"February 15, 2011",,,,"Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A): During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.; Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A): During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.; Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1): During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.; Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2): During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.; Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2): During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.; Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2): During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.; MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D): Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.; MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D): Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.; MEL: Pembrolizumab 10 mg/kg Q2W (Part B): Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.; NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F): Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.; NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F): Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.; NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F): Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.; NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled): Participants were to receive pembrolizumab IV at a dose of 2 mg/kg Q3W. No participants were enrolled in this arm.; NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled): Participants were to receive pembrolizumab IV at a dose of 5 mg/kg Q3W. No participants were enrolled in this arm.; NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled): Participants were to receive pembrolizumab IV at a dose of 10 mg/kg Q3W. No participants were enrolled in this arm.",,,,,,,,,,,,,No
